Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7444531 | 0.99 | ALDH1A1 (0.45) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL27703135 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL27697836 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL1731417 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL27703130 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL1731415 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL11169957 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL1626512 | 0.86 | ALDH1A1 (0.44) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL27516607 | 0.86 | ALDH1A1 (0.44) | ALDH1A1SYKKMT2AMAPK1L3MBTL1 | |
| SCHEMBL3404332 | 0.85 | KMT2A (0.50) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086098-B1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2006-04-05 | — | — | EP | disclosed |
| CN-1135236-C | 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | �ճ�˹�عɷݹ�˾ | 2004-01-21 | — | — | CN | disclosed |
| CN-1133647-C | Heterocyclic compound used as leucocyte adherence inhibitor and VLA-4 antagonist | �ճ�˹�عɷݹ�˾ | 2004-01-07 | — | — | CN | disclosed |
| US-6660728-B2 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH AND GENENTECH, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6566366-B1 | For therapy of tumor growth, osteoporosis, inflammation and cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| CN-1104421-C | Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 2003-04-02 | — | — | CN | disclosed |
| CN-1064352-C | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 2001-04-11 | — | — | CN | disclosed |
| EP-1086098-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| EP-0960882-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999059992-A1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
| CN-1218047-A | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-06-02 | — | — | CN | disclosed |
| CN-1216767-A | Novel 5-membered ring heterocycles, their prepn. their use and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-05-19 | — | — | CN | disclosed |
| CN-1193022-A | Heterocyclic compound used as leucocyte adherence inhibitor and VLA-4 antagonist | HOECHST AG (DE) | 1998-09-16 | — | — | CN | disclosed |
| CN-1187490-A | 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| CN-1179418-A | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-04-22 | — | — | CN | disclosed |
| CN-1174836-A | Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | ASGR1, PTMS, B3GNT2 | ALDH1A1 2329/4885SYK 3577/4885KMT2A 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.